While deposition of MASP-2, C4d, C5b-9 and MBL was shown in lung tissue from COVID-19 patients, increased complement activation product levels were observed in patient sera from SARS-CoV-2 infected individuals (13, 14, 23). This evidence concerns the gene MASP2 and COVID-19.